Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.69 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 3/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1436885 | 0.93 | MDM2 (0.68) | MDM2PFKFB4FABP4FABP5IDO1 | |
| SCHEMBL1436916 | 0.93 | MDM2 (0.60) | MDM2IDO1SLC22A12GP6NPC1 | |
| SCHEMBL9894070 | 0.88 | MDM2 (0.64) | MDM2PFKFB4CNR1SLC22A12KDM4C | |
| SCHEMBL9893889 | 0.88 | MDM2 (0.64) | MDM2PFKFB4IDO1CNR1SLC22A12 | |
| SCHEMBL1437412 | 0.87 | MDM2 (0.70) | MDM2PFKFB4FABP4FABP5IDO1 | |
| SCHEMBL9893644 | 0.87 | MDM2 (0.60) | MDM2PFKFB4CNR1SLC22A12KDM4C | |
| SCHEMBL9893758 | 0.86 | MDM2 (0.64) | MDM2PFKFB4FABP4FABP5IDO1 | |
| SCHEMBL1438114 | 0.86 | MDM2 (0.61) | MDM2PFKFB4IDO1CNR1SLC22A12 | |
| SCHEMBL1444094 | 0.85 | MDM2 (0.59) | MDM2CNR1 | |
| SCHEMBL1437268 | 0.84 | MDM2 (0.64) | MDM2PFKFB4FABP4FABP5IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574785-A | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885PFKFB4 3641/4885FABP4 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.